- Home
- FBYD vs ANVS Comparison
FBYD vs ANVS Comparison
Compare FBYD & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBYD | ANVS |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | 243 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.1M | 55.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBYD | ANVS |
|---|---|---|
| Price | $8.25 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 122.9K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $14,896,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $209.00 | ★ N/A |
| Revenue Growth | ★ 120.85 | N/A |
| 52 Week Low | $3.71 | $1.04 |
| 52 Week High | $29.02 | $5.50 |
Technical Indicators
Market Signals| Indicator | FBYD | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 46.55 |
| Support Level | $6.01 | $1.04 |
| Resistance Level | $8.87 | $2.43 |
| Average True Range (ATR) | 0.72 | 0.09 |
| MACD | 0.28 | 0.04 |
| Stochastic Oscillator | 92.15 | 78.21 |
Price Performance
Historical ComparisonAbout FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.